Potential drug for treating deadly brain cancer

September 4, 2012
Current therapies eradicate tumour cells initially but cancer stem cells may allow for tumours to recur. AntimiR-138 can destroy cancer stem cells and hence tumour growth.

(Medical Xpress)—A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults − glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour. The research findings were published on Aug 23 in the scientific journal, Cell Reports from Cell Press.

The scientists found that the biomarker, miR-138, is highly expressed in cancer stem cells compared to normal . They thus carried out in vitro experiments to deplete miR-138 in these cancer stem cells with a potential drug, antimiR-138, to observe the effect. They found that when miR-138 is depleted, the are completely destroyed. This is an important breakthrough as current therapies such as and surgical methods proved to be inadequate in treating these brain tumours, which tend to re-grow from cancer stem cells and become extremely lethal. 

Dr Sampath said, "In this study we have identified a master regulator, miR-138, which is essential for the progression and relapse of a deadly form of brain cancer. By targeting this regulator we can effectively prevent the recurrence of this lethal form of cancer. This promising finding will pave the way for the development of a to successfully treat the aggressive forms of brain cancer."

Studies were also done in mice to determine whether antimiR-138 could effectively inhibit the growth of tumours. These experiments were conducted with a control drug as well, revealing that tumours continued to be present when mice were injected with the control, while injection with the antimiR-138 showed no tumour growth after nine months.

Dr Alan Colman, Executive Director of Singapore Stem Cell Consortium and a Principal Investigator at IMB said, " are a particularly devastating and lethal form of cancer. As with a growing number of other cancers, evidence is accumulating that the persistence and chemo-resistance of this cancer is due to the presence of glioma stem cells (GSCs).  In this exciting publication, Sampath and colleagues indicate that in the tumours, these GSCs express the microRNA-138 (miR-138) and that the targeted elimination of this RNA markedly reduced the growth and survival of GSCs in cell culture.  This work highlights the possible significance of miR-138 as a prognostic biomarker and also suggests miR-138 synthesis as a target for therapeutic intervention."

Prof Sir David Lane, Chief Scientist at A*STAR, added, "These findings will facilitate the translation of basic research into clinical applications such as targeted drug design to treat brain cancer."

Explore further: To combat deadly brain cancer, target the stem cells

More information: Xin Hui Derryn Chan et al., "Targeting Glioma Stem Cells by Functional Inhibition of a Prosurvival OncomiR-138 in Malignant Gliomas". Cell Press. August 23.

Related Stories

To combat deadly brain cancer, target the stem cells

July 7, 2011
Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer. In the July 8th issue of the journal Cell, a Cell Press publication, a new study identifies an enzyme found ...

miR loss may power maligant transformation in chronic leukemia

July 5, 2012
Loss of a particular microRNA in chronic lymphocytic leukemia shuts down normal cell metabolism and turns up alternative mechanisms that enable cancer cells to produce the energy and build the molecules they need to proliferate ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.